The European Medicines Agency (EMEA) advises sponsors of epileptic disorder treatments in Phase III trials to use certain primary endpoints and include an adequate number of geriatric patients.

欧洲药品局(emea)建议：三期临床试验治疗癫痫症的发起者应当包含足够数量的老年患者。